All In Biotech

Drug Trial Radar · NCT05464784

MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MN-001 in Patients Diagnosed With Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 22, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
MediciNovaIndustry
Sponsor type
Industry
First posted
Jul 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The design of the Phase 2 clinical trial includes the following elements: * Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S. * Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks. * The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2) change from baseline in fasting serum triglycerides at Week 24. FibroScan® is a non-invasive, quantitative, and accurate measure of liver fat content commonly used in early phase trials to measure treatment response. * Secondary endpoints include safety and tolerability and changes in lipid profile (HDL-C, LDL-C, and total cholesterol).

Conditions

  • Diabetes Mellitus, Type 2
  • Hypertriglyceridemia
  • Non-Alcoholic Fatty Liver Disease

Interventions

  • MN-001Drug

    MN-001 is a novel, orally bioavailable small molecule compound

  • MN-001 placeboDrug

    The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in controlled attenuation parameter (CAP) score by sound-based elastography at Week 24Time frame: Week 24
  2. Mean change from baseline in fasting serum triglyceride levels at Week 24Time frame: Week 24

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jubilee Clinical Research, Inc.

    Las Vegas, Nevada

  • Pinnacle Clinical Research at South Texas Research Institute

    Edinburg, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.